The Impact of Cognitive Behavioral Therapy for Insomnia (CBT-I) on Glycemic Control in Older Type 2 Diabetes (T2D) Comorbid With Insomnia

Launched by CHINESE UNIVERSITY OF HONG KONG · Apr 1, 2021

Keywords

ClinConnect Summary

This clinical trial is exploring how Cognitive Behavioral Therapy for Insomnia (CBT-I) can help improve blood sugar control in older adults with Type 2 diabetes who also have insomnia. The researchers want to see if CBT-I, which is a type of therapy designed to help people sleep better, can lead to improvements in sleep quality, mental health, and thinking skills compared to standard care. The study is set to take place in Hong Kong and will involve older Chinese adults aged 60 and above who have diabetes that isn’t well controlled and significant insomnia.

To participate, individuals must be at least 60 years old, have Type 2 diabetes with a specific level of blood sugar, and have trouble sleeping. However, those with certain conditions, such as significant depression or cognitive issues, or those who use certain medications that affect sleep, won’t be eligible. Participants can expect to receive therapy aimed at improving their sleep, and the study will monitor their blood sugar levels and overall health. This research could help identify new ways to support older adults in managing their diabetes and sleep problems effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Aged ≥60 years;
• • 2. T2D with suboptimal glycemic control defined as HbA1c 7.1-10%;
• • 3. Chinese ethnicity;
• • 4. Comorbid with insomnia having ISI score \>10;
• • 5. Able and willing to give informed written consent
• Exclusion criteria:
• • 1. Cognitive impairment (HK-MoCA score of ≤22);
• • 2. Depression (GDS-15 score \>8) and other psychiatric disorders e.g. generalized anxiety disorder, restless leg syndrome, schizophrenia to be elucidated by history from research nurse and questionnaires;
• • 3. Benign prostatic hypertrophy by history and/or elevated PSA and any other chronic medical condition that is likely to affect sleep e.g. chronic pain;
• • 4. Concurrent use of hypnotic drugs, psychotic medications and any drugs that are known to affect sleep;
• • 5. Cerebrovascular accidents, vascular dementia, or any condition that are known to affect cognitive function;
• • 6. Shift workers;
• • 7. Haemoglobinopathies, renal failure, need of regular blood transfusion or any other conditions which will affect the validity of HbA1c in measurement of glycemia;
• • 8. Any condition, as judged by the investigators, as ineligible to participate in this study.